Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Jun;100(6):e240-3.
doi: 10.3324/haematol.2014.119214. Epub 2015 Feb 14.

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway

Knut B Smeland  1 , Cecilie E Kiserud  2 , Grete F Lauritzsen  3 , Unn-Merete Fagerli  4 , Ragnhild S Falk  5 , Øystein Fluge  6 , Alexander Fosså  3 , Arne Kolstad  3 , Jon H Loge  7 , Martin Maisenhölder  8 , Stein Kvaløy  9 , Harald Holte  3
Affiliations
Multicenter Study

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway

Knut B Smeland et al. Haematologica. 2015 Jun.
No abstract available

Keywords: autologous stem cell transplantation; high-dose therapy; mortality; non-Hodgkin lymphoma; survival.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier curves showing overall survival after high-dose therapy with autologous stem cell transplantation (HDT-ASCT) for relapsed/refractory Hodgkin lymphoma for the entire cohort (n=150) (A), and by treatment period (B), time from diagnosis to HDT-ASCT (C) and disease status at HDT-ASCT (D). Observation time are calculated from time of HDT-ASCT to death or cut off at June 30th 2014. P-values are obtained from log rank tests. CR: complete remission; CRu: complete remission unconfirmed; PR: partial remission and SD: stable disease.
Figure 2.
Figure 2.
Conditional overall survival after high-dose therapy with autologous stem cell support (HDT-ASCT) for Hodgkin lymphoma (calculated using the life-table method). Curves are given if 10 or more patients were alive at start of follow-up year. HDT: high dose therapy; OS: overall survival.
See this image and copyright information in PMC

References

    1. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013; 14(10):943–952. - PubMed
    1. Rancea M, Tresckow von B, Monsef I, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. Crit Rev Oncol Hematol. 2014;92(1):1–10. - PubMed
    1. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054. - PubMed
    1. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002; 359(9323):2065–2071. - PubMed
    1. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. 2005;105(11):4215–4222. - PMC - PubMed